

Jan Cornel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2876832/publications.pdf>

Version: 2024-02-01

267
papers

44,501
citations

10986

71
h-index

1980

206
g-index

284
all docs

284
docs citations

284
times ranked

31796
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	27.0	6,227
2	Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet, The, 1999, 353, 2001-2007.	13.7	4,616
3	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	27.0	4,179
4	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
5	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	27.0	1,426
6	Rosuvastatin in Older Patients with Systolic Heart Failure. New England Journal of Medicine, 2007, 357, 2248-2261.	27.0	1,330
7	Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet, The, 1997, 349, 1429-1435.	13.7	1,241
8	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
9	Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine, 2020, 383, 1838-1847.	27.0	1,010
10	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1833-1842.	13.7	948
11	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	13.7	934
12	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine, 2011, 365, 699-708.	27.0	918
13	Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. New England Journal of Medicine, 2010, 362, 1363-1373.	27.0	851
14	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 671-678.	1.6	817
15	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. JAMA - Journal of the American Medical Association, 2016, 316, 2373.	7.4	813
16	nâ€“3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	27.0	810
17	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	27.0	765
18	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine, 2012, 366, 20-33.	27.0	701

#	ARTICLE	IF	CITATIONS
19	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, The, 2018, 391, 319-328.	13.7	628
20	Accuracy of Currently Available Techniques for Prediction of Functional Recovery After Revascularization in Patients With Left Ventricular Dysfunction Due to Chronic Coronary Artery Disease: Comparison of Pooled Data. Journal of the American College of Cardiology, 1997, 30, 1451-1460.	2.8	488
21	Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes. New England Journal of Medicine, 2005, 353, 1095-1104.	27.0	485
22	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2010, 31, 3006-3016.	2.2	389
23	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation, 2019, 139, 1289-1299.	1.6	384
24	Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Circulation, 2010, 122, 1056-1067.	1.6	354
25	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2011, 32, 2933-2944.	2.2	335
26	Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. Journal of the American College of Cardiology, 1999, 34, 163-169.	2.8	318
27	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.8	296
28	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England Journal of Medicine, 2019, 381, 1309-1320.	27.0	255
29	Prediction of Improvement of Regional Left Ventricular Function After Surgical Revascularization. Circulation, 1995, 91, 2748-2752.	1.6	250
30	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ: British Medical Journal, 2011, 342, d3527-d3527.	2.3	246
31	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2019, 7, 618-628.	11.4	207
32	Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. Journal of the American College of Cardiology, 2009, 54, 1850-1859.	2.8	200
33	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. JAMA - Journal of the American Medical Association, 2012, 308, 1785.	7.4	200
34	Prediction of recovery of myocardial dysfunction after revascularization comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. Journal of the American College of Cardiology, 1996, 28, 558-564.	2.8	198
35	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	6.1	196
36	The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy. JACC: Cardiovascular Imaging, 2018, 11, 1274-1284.	5.3	196

#	ARTICLE	IF	CITATIONS
37	Impaired glucose metabolism predicts mortality after a myocardial infarction. International Journal of Cardiology, 2001, 79, 207-214.	1.7	195
38	Inhibition of Interleukin-1 β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2018, 71, 2405-2414.	2.8	186
39	Time Course of Functional Recovery of Stunned and Hibernating Segments After Surgical Revascularization. Circulation, 2001, 104, I-314-I-318.	1.6	180
40	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y ₁₂ inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, The, 2017, 389, 1799-1808.	13.7	174
41	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal, 2014, 35, 2083-2093.	2.2	171
42	Biphasic Response to Dobutamine Predicts Improvement of Global Left Ventricular Function After Surgical Revascularization in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 1998, 31, 1002-1010.	2.8	159
43	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	13.7	155
44	Design and Optimization of a Combined Cooling/Antisolvent Crystallization Process. Crystal Growth and Design, 2009, 9, 1124-1136.	3.0	154
45	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	2.8	154
46	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care, 2016, 39, 2304-2310.	8.6	142
47	Possible Bradycardic Mode of Death and Successful Pacemaker Treatment in a Large Family with Features of Long QT Syndrome Type 3 and Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2001, 12, 630-636.	1.7	140
48	Safety of dobutamine-atropine stress echocardiography in patients with suspected or proven coronary artery disease. American Journal of Cardiology, 1994, 73, 456-459.	1.6	138
49	Akinesis becoming dyskinesis during high-dose dobutamine stress echocardiography: A marker of myocardial ischemia or a mechanical phenomenon?. American Journal of Cardiology, 1994, 73, 896-899.	1.6	135
50	Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet, The, 2007, 369, 827-835.	13.7	132
51	Quantitative Application of in Situ ATR-FTIR and Raman Spectroscopy in Crystallization Processes. Industrial & Engineering Chemistry Research, 2008, 47, 4870-4882.	3.7	121
52	Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A β 1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. European Journal of Heart Failure, 2009, 11, 281-291.	7.1	120
53	The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA β CER) trial: study design and rationale. American Heart Journal, 2009, 158, 327-334.e4.	2.7	120
54	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. European Heart Journal, 2021, 42, 2765-2775.	2.2	119

#	ARTICLE	IF	CITATIONS
55	Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventerâ€“Alkmaar heart failure study. <i>Heart</i> , 2007, 93, 819-825.	2.9	114
56	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet</i> , The, 2016, 387, 349-356.	13.7	109
57	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
58	Prognostic value of predischARGE dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. <i>Journal of the American College of Cardiology</i> , 2003, 41, 596-602.	2.8	104
59	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Nonâ€“ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
60	Cardiac Imaging for Risk Stratification With Dobutamine-Atropine Stress Testing in Patients With Chest Pain. <i>Circulation</i> , 1997, 96, 137-147.	1.6	92
61	Safety and prognostic value of early dobutamineâ€“atropine stress echocardiography in patients with spontaneous chest pain and a non-diagnostic electrocardiogram. <i>European Heart Journal</i> , 2000, 21, 397-406.	2.2	90
62	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	2.7	88
63	A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. <i>European Heart Journal</i> , 2013, 34, 2481-2489.	2.2	85
64	Dobutamine-atropine stress echocardiography and clinical data for predicting late cardiac events in patients with suspected coronary artery disease. <i>American Journal of Medicine</i> , 1994, 97, 119-125.	1.5	82
65	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. <i>Circulation</i> , 2020, 142, 1996-1998.	1.6	81
66	Prediction of improvement of ventricular function after first acute myocardial infarction using low-dose dobutamine stress echocardiography. <i>American Journal of Cardiology</i> , 1994, 74, 853-856.	1.6	80
67	Prediction of Improvement of Contractile Function in Patients With Ischemic Ventricular Dysfunction After Revascularization by Fluorine-18 Fluorodeoxyglucose Single-Photon Emission Computed Tomography. <i>Journal of the American College of Cardiology</i> , 1997, 30, 377-383.	2.8	79
68	Experimental Characterization and Population Balance Modeling of the Polymorph Transformation of <sc>l</sc>-Glutamic Acid. <i>Crystal Growth and Design</i> , 2009, 9, 243-252.	3.0	79
69	Usefulness and limitations of dobutamineâ€“atropine stress echocardiography for the diagnosis of coronary artery disease in patients with left bundle branch block. A multicentre study. <i>European Heart Journal</i> , 2000, 21, 1666-1673.	2.2	77
70	Rate Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. <i>American Heart Journal</i> , 2006, 152, 420-426.	2.7	76
71	Improved identification of coronary artery disease in patients with left bundle branch block by use of dobutamine stress echocardiography and comparison with myocardial perfusion tomography. <i>American Journal of Cardiology</i> , 1995, 76, 321-325.	1.6	74
72	Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 35-41.	2.1	72

#	ARTICLE	IF	CITATIONS
73	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. American Heart Journal, 2019, 218, 46-56.	2.7	72
74	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2016, 67, 2135-2144.	2.8	66
75	Relationship between exercise echocardiography and perfusion single-photon emission computed tomography in patients with single-vessel coronary artery disease. American Heart Journal, 1992, 124, 75-83.	2.7	57
76	Prognostic Value of Dobutamine-Atropine Stress Technetium-99m Sestamibi Perfusion Scintigraphy in Patients With Chest Pain. Journal of the American College of Cardiology, 1996, 28, 447-454.	2.8	57
77	Precipitation and Transformation of the Three Polymorphs of α -Mannitol. Industrial & Engineering Chemistry Research, 2010, 49, 5854-5862.	3.7	56
78	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 2018, 71, 489-496.	2.8	56
79	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2016, 39, 709-716.	8.6	55
80	Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. Journal of Nuclear Medicine, 2001, 42, 79-86.	5.0	55
81	Dobutamine-induced hypoperfusion without transient wall motion abnormalities: Less severe ischemia or less severe stress?. Journal of the American College of Cardiology, 1996, 27, 323-329.	2.8	54
82	Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2012, 164, 334-342.e1.	2.7	53
83	Relation between contractile response of akinetic segments during dobutamine stress echocardiography and myocardial ischemia assessed by simultaneous thallium-201 single-photon emission computed tomography. American Journal of Cardiology, 1996, 77, 955-959.	1.6	52
84	Myocardial β -adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 443-447.	6.4	52
85	Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. European Heart Journal, 1992, 13, 213-219.	2.2	50
86	Evaluation by quantitative 99m-technetium MIBI SPECT and echocardiography of myocardial perfusion and wall motion abnormalities in patients with dobutamine-induced ST-segment elevation. American Journal of Cardiology, 1995, 76, 441-448.	1.6	50
87	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	2.8	49
88	Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. Journal of the American College of Cardiology, 1996, 28, 447-454.	2.8	48
89	Experimental evidence of a delta-shock in nonlinear chromatography. Journal of Chromatography A, 2010, 1217, 2002-2012.	3.7	48
90	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1193-1203.	1.6	47

#	ARTICLE	IF	CITATIONS
91	Relaxivity Studies on Dinitroxide and Polynitroxyl Functionalized Dendrimers: Effect of Electron Exchange and Structure on Paramagnetic Relaxation Enhancement. <i>Journal of Physical Chemistry A</i> , 2003, 107, 8467-8475.	2.5	46
92	Dobutamine-Atropine Stress Echocardiography in Elderly Patients Unable to Perform an Exercise Test. <i>Archives of Internal Medicine</i> , 1994, 154, 2681.	3.8	45
93	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	2.2	45
94	PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2571-2573.	5.3	44
95	Detection of left coronary artery stenosis by transoesophageal echocardiography. <i>European Heart Journal</i> , 1988, 9, 1162-1166.	2.2	43
96	Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction. <i>European Heart Journal</i> , 1998, 19, 1712-1718.	2.2	43
97	Intensive Glucose Regulation in Hyperglycemic Acute Coronary Syndrome. <i>JAMA Internal Medicine</i> , 2013, 173, 1896.	5.1	43
98	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 443-454.	1.0	43
99	N-terminal pro-B-type natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. <i>American Heart Journal</i> , 2007, 153, 485-492.	2.7	41
100	Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. <i>American Journal of Medicine</i> , 2022, 135, 32-38.	1.5	41
101	Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHIFT study. <i>American Heart Journal</i> , 2018, 196, 36-48.	2.7	40
102	Intracoronary albuterol. Its effects on left ventricular hemodynamics, function, and coronary sinus flow in humans. <i>Circulation</i> , 1993, 88, 2123-2127.	1.6	39
103	Prognostic significance of normal dobutamine-atropine stress sestamibi scintigraphy in women with chest pain. <i>American Journal of Cardiology</i> , 1996, 77, 1057-1061.	1.6	39
104	The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population. <i>Cardiology</i> , 2008, 110, 271-282.	1.4	39
105	Cystatin C for Enhancement of Risk Stratification in Non-ST Elevation Acute Coronary Syndrome Patients with an Increased Troponin T. <i>Clinical Chemistry</i> , 2009, 55, 1118-1125.	3.2	38
106	Elevated admission glucose is associated with increased long-term mortality in myocardial infarction patients, irrespective of the initially applied reperfusion strategy. <i>American Heart Journal</i> , 2010, 160, 412-419.	2.7	38
107	Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction. <i>Journal of the American Society of Echocardiography</i> , 1996, 9, 27-32.	2.8	37
108	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial. <i>American Heart Journal</i> , 2011, 161, 261-268.e2.	2.7	36

#	ARTICLE	IF	CITATIONS
109	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 2017, 186, 91-99.	2.7	36
110	Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study. International Journal of Cardiology, 2017, 235, 124-132.	1.7	36
111	Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. American Heart Journal, 1996, 131, 1088-1096.	2.7	35
112	Agreement and disagreement between "metabolic viability" and "contractile reserve" in akinetic myocardium. Journal of Nuclear Cardiology, 1999, 6, 383-388.	2.1	35
113	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart, 2017, 103, 1168-1176.	2.9	34
114	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 2019, 140, 1578-1589.	1.6	34
115	Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias. European Heart Journal, 2008, 30, 645-654.	2.2	33
116	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y ₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. Journal of the American Heart Association, 2019, 8, e011139.	3.7	33
117	Percutaneous Coronary Intervention With Off-Site Cardiac Surgery Backup for Acute Myocardial Infarction as a Strategy to Reduce Door-to-Balloon Time. American Journal of Cardiology, 2007, 100, 1353-1358.	1.6	31
118	Impact of Severity of Coronary Artery Stenosis and the Collateral Circulation on the Functional Outcome of Dyssynergic Myocardium After Revascularization in Patients With Healed Myocardial Infarction and Chronic Left Ventricular Dysfunction. American Journal of Cardiology, 1997, 79, 883-888.	1.6	30
119	Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability. International Journal of Cardiovascular Imaging, 1997, 13, 145-155.	0.6	29
120	Early Invasive Versus Selective Strategy for "ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2017, 69, 1883-1893.	2.8	29
121	Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS ONE, 2020, 15, e0237665.	2.5	29
122	Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATElet inhibition and patient outcomes (PLATO) trial. American Heart Journal, 2013, 166, 474-480.	2.7	28
123	Evaluation of collateral blood flow by myocardial contrast enhanced echocardiography.. Heart, 1988, 59, 20-22.	2.9	27
124	Accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery stenosis in patients with myocardial infarction: the impact of extent and severity of left ventricular dysfunction.. Heart, 1996, 76, 123-128.	2.9	27
125	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. Thrombosis and Haemostasis, 2014, 112, 883-891.	3.4	27
126	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. Journal of the American College of Cardiology, 2021, 78, 859-866.	2.8	27

#	ARTICLE	IF	CITATIONS
127	Estimating Crystal Growth Rates Using in situ ATR-FTIR and Raman Spectroscopy in a Calibration-Free Manner. Industrial & Engineering Chemistry Research, 2009, 48, 10740-10745.	3.7	26
128	Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHIFT study. Kidney International, 2018, 93, 952-960.	5.2	26
129	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. EuroIntervention, 2014, 10, 431-438.	3.2	26
130	Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis, 2021, 334, 93-100.	0.8	25
131	Sequential (201)Tl imaging and dobutamine echocardiography to enhance accuracy of predicting improved left ventricular ejection fraction after revascularization. Journal of Nuclear Medicine, 2002, 43, 795-802.	5.0	25
132	T-Wave normalization during dobutamine echocardiography for diagnosis of viable myocardium. American Journal of Cardiology, 1995, 75, 505-507.	1.6	24
133	Quantitative angiographic measurements of isolated left anterior descending coronary artery stenosis correlation with exercise echocardiography and technetium-99m 2-methoxy isobutyl isonitrile single-photon emission computed tomography. Journal of the American College of Cardiology, 1995, 25, 1486-1491.	2.8	24
134	Akinesis Becoming Dyskinesis During Dobutamine Stress Echocardiography. Chest, 1996, 110, 155-158.	0.8	24
135	F18-fluorodeoxyglucose single-photon emission computed tomography predicts functional outcome of dyssynergic myocardium after surgical revascularization. Journal of Nuclear Cardiology, 1997, 4, 302-308.	2.1	24
136	Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study. European Journal of Heart Failure, 2005, 7, 910-920.	7.1	24
137	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes, Obesity and Metabolism, 2017, 19, 1587-1593.	4.4	24
138	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical Cardiology, 2019, 42, 498-505.	1.8	24
139	Comparison of fluorine-18-FDG with rest-redistribution thallium-201 SPECT to delineate viable myocardium and predict functional recovery after revascularization. Journal of Nuclear Medicine, 1998, 39, 1481-6.	5.0	24
140	Dobutamine-atropine stress myocardial perfusion SPECT imaging in the diagnosis of graft stenosis after coronary artery bypass grafting*1. Journal of Nuclear Cardiology, 1998, 5, 491-497.	2.1	23
141	Colchicine in Stable Coronary Artery Disease. Clinical Therapeutics, 2019, 41, 30-40.	2.5	23
142	Relation between ST segment elevation during dobutamine stress test and myocardial viability after a recent myocardial infarction.. Heart, 1997, 77, 115-121.	2.9	22
143	Patient work in end-stage heart failure: a prospective longitudinal multiple case study. Palliative Medicine, 2006, 20, 25-33.	3.1	22
144	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. American Heart Journal, 2014, 168, 76-87.e1.	2.7	22

#	ARTICLE	IF	CITATIONS
145	Vorapaxar with or without clopidogrel after nonâ€“ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. American Heart Journal, 2014, 168, 869-877.e1.	2.7	21
146	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. European Heart Journal, 2021, 42, 2973-2985.	2.2	21
147	The prognostic value of markers of inflammation in patients with troponin Tâ€“negative chest pain before discharge from the emergency department. American Journal of Medicine, 2003, 115, 521-528.	1.5	20
148	Safety and efficacy of a nurse-led clinic for post-operative coronary artery bypass grafting patients. International Journal of Cardiology, 2006, 106, 111-115.	1.7	20
149	Assessment of patients after coronary artery bypass grafting by dobutamine stress echocardiography. American Journal of Cardiology, 1996, 77, 1234-1236.	1.6	19
150	Assessment of myocardial viability by dobutamine stress echocardiography. Current Opinion in Cardiology, 1996, 11, 621-626.	1.8	19
151	Prediction of improvement of ventricular function after revascularization: 18F-fluorodeoxyglucose single-photon emission computed tomography vs low-dose dobutamine echocardiography. European Heart Journal, 1997, 18, 941-948.	2.2	19
152	Calibration-Free Quantitative Application of in Situ Raman Spectroscopy to a Crystallization Process. Analytical Chemistry, 2008, 80, 9240-9249.	6.5	19
153	The Effect of Multiple-Dose Oral Lomefloxacin on Theophylline Metabolism in Man. Chest, 1990, 98, 1440-1444.	0.8	18
154	Abnormal contractile responses during dobutamine stress echocardiography in patients with idiopathic dilated cardiomyopathy. European Journal of Heart Failure, 2001, 3, 429-436.	7.1	18
155	The impact of admission plasma glucose on long-term mortality after STEMI and NSTEMI myocardial infarction. International Journal of Cardiology, 2007, 121, 215-217.	1.7	18
156	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2014, 168, 68-75.e2.	2.7	18
157	Long-term outcomes for women versus men with unstable angina/nonâ€“ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial. American Heart Journal, 2015, 170, 695-705.e5.	2.7	18
158	T wave normalization during dobutamine stress testing in patients with non-Q wave myocardial infarction. A marker of myocardial ischaemia?. European Heart Journal, 1996, 17, 526-531.	2.2	17
159	The direct inverse method: A novel approach to estimate adsorption isotherm parameters. Journal of Chromatography A, 2010, 1217, 1934-1941.	3.7	17
160	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes (from the Tj ETQq0 0 0 gBT /Overlock 10 T	2.2	17
161	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005858.	2.2	17
162	Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. Journal of Nuclear Medicine, 1999, 40, 1866-73.	5.0	17

#	ARTICLE	IF	CITATIONS
163	Correlation of coronary stenosis by quantitative coronary arteriography with exercise echocardiography. American Journal of Cardiology, 1995, 75, 287-290.	1.6	16
164	Monitoring size and shape during cooling crystallization of ascorbic acid. Chemical Engineering Science, 2009, 64, 163-171.	3.8	16
165	Anatomical versus Functional Testing for Coronary Artery Disease. New England Journal of Medicine, 2015, 373, 89-91.	27.0	16
166	Prediction of Recovery of Myocardial Dysfunction After Revascularization Comparison of Fluorine-18 Fluorodeoxyglucose/Thallium-201 SPECT, Thallium-201 Stressâ€“Reinjection SPECT and Dobutamine Echocardiography. Journal of the American College of Cardiology, 1996, 28, 558-564.	2.8	16
167	Coronary artery disease in patients with atypical chest pain with and without diabetes mellitus assessed with coronary CT angiography. BMJ Open Diabetes Research and Care, 2014, 2, e000004.	2.8	15
168	Delayed recovery of hibernating myocardium after surgical revascularization: Implications for discrepancy between metabolic imaging and dobutamine echocardiography for assessment of myocardial viability. Journal of Nuclear Cardiology, 1999, 6, 685-687.	2.1	14
169	ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in nonâ€“ST-elevation acute coronary syndromes. Journal of Electrocardiology, 2007, 40, 408-415.	0.9	14
170	Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study. Thrombosis and Haemostasis, 2019, 119, 1947-1955.	3.4	14
171	A multidisciplinary care pathway for the evaluation of falls and syncope in geriatric patients. European Geriatric Medicine, 2015, 6, 487-494.	2.8	13
172	Stress-induced left ventricular dysfunction in silent and symptomatic myocardial ischemia during dobutamine stress test. American Journal of Cardiology, 1995, 75, 1112-1115.	1.6	12
173	Comparison between 360Â° and 180Â° data sampling in thallium-201 rest-redistribution single-photon emission tomography to predict functional recovery after revascularization. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 516-522.	2.1	12
174	Predictive Accuracy of Echocardiographic Response of Mildly Dyssynergic Myocardial Segments to Low-Dose Dobutamine. American Journal of Cardiology, 1997, 80, 1481-1484.	1.6	12
175	Inhibition of nonlinear acoustic cavitation dynamics in liquid CO2. Journal of Chemical Physics, 2007, 126, 064508.	3.0	12
176	Characteristics and prognostic value of right ventricular (dys)function in patients with nonâ€“ischaemic dilated cardiomyopathy assessed with cardiac magnetic resonance imaging. ESC Heart Failure, 2021, 8, 1055-1063.	3.1	12
177	Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiratorY distress syndrome in hospitalized patients with SARS-COV-2 Infection Disease. American Heart Journal, 2020, 226, 60-68.	2.7	12
178	Cardiac 18F-FDG-SPET studies in patients with non-insulin-dependent diabetes mellitus during hyperinsulinaemic euglycaemic clamping. Nuclear Medicine Communications, 1997, 18, 200-206.	1.1	11
179	High-pitch prospective ECG-triggered helical coronary computed tomography angiography in clinical practice: image quality and radiation dose. International Journal of Cardiovascular Imaging, 2015, 31, 125-133.	1.5	11
180	Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0260844.	2.5	11

#	ARTICLE	IF	CITATIONS
181	Dobutamine thallium-201 SPECT imaging for assessment of peri-infarction and remote myocardial ischemia. <i>Journal of Nuclear Medicine</i> , 1996, 37, 1951-6.	5.0	11
182	Effect of papaverine administration on myocardial echocontrast distribution. <i>American Heart Journal</i> , 1987, 114, 1248-1249.	2.7	10
183	Endothelial dysfunction and reduced myocardial perfusion reserve in heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 2003, 91, 497-500.	1.6	10
184	Independent prognostic value of coronary artery calcium score and coronary computed tomography angiography in an outpatient cohort of low to intermediate risk chest pain patients. <i>Netherlands Heart Journal</i> , 2016, 24, 332-342.	0.8	10
185	Comprehensive analysis of aortic valve vegetation with anyplane, paraplane, and three-dimensional echocardiography. <i>European Heart Journal</i> , 1996, 17, 318-320.	2.2	9
186	FDG SPECT in the assessment of myocardial viability: Comparison with dobutamine echo. <i>European Heart Journal</i> , 1997, 18, 124-129.	2.2	9
187	N-Terminal Pro B-Type Natriuretic Peptide Identifies Patients with Chest Pain at High Long-term Cardiovascular Risk. <i>American Journal of Medicine</i> , 2011, 124, 961-969.	1.5	9
188	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 12-20.	3.4	9
189	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APIxaban for PRevention of Acute ISchemic Events 2 trial. <i>American Heart Journal</i> , 2015, 169, 531-538.	2.7	9
190	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-“ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 1214-1226.	3.2	9
191	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	6.1	9
192	Electronic health records to facilitate continuous detection of familial hypercholesterolemia. <i>Atherosclerosis</i> , 2020, 310, 83-87.	0.8	9
193	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. <i>Circulation</i> , 2022, 145, 626-628.	1.6	9
194	Altered myocardial perfusion during dobutamine stress testing in silent versus symptomatic myocardial ischaemia assessed by quantitative MIBI SPET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1354-1360.	2.1	8
195	Prognostic Implications of a Normal Dobutamine-Atropine Stress Echocardiogram in Patients with Chest Pain. <i>Journal of the American Society of Echocardiography</i> , 1998, 11, 606-611.	2.8	8
196	GRACE and TIMI risk scores but not stress imaging predict long-term cardiovascular follow-up in patients with chest pain after a rule-out protocol. <i>Netherlands Heart Journal</i> , 2011, 19, 324-330.	0.8	8
197	Quantitative assessment of myocardial blood flow by contrast two-dimensional echocardiography: initial clinical observations. <i>American Journal of Physiologic Imaging</i> , 1987, 2, 56-60.	0.1	8
198	Potential and limitations of Tc-99m sestamibi scintigraphy for the diagnosis of myocardial viability. <i>Herz</i> , 1994, 19, 19-27.	1.1	8

#	ARTICLE	IF	CITATIONS
199	Digoxin in Patients with Heart Failure. New England Journal of Medicine, 1997, 337, 129-131.	27.0	7
200	Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCSâ€f2 glucose trial. Diabetic Medicine, 2011, 28, 1168-1175.	2.3	7
201	Ruling Out Coronary Artery Disease in Women with Atypical Chest Pain: Results of Calcium Score Combined with Coronary Computed Tomography Angiography and Associated Radiation Exposure. Journal of Women's Health, 2015, 24, 550-556.	3.3	7
202	Repeated Echocardiograms Do Not Provide Incremental Prognostic Value to Single Echocardiographic Assessment in Minimally Symptomatic Patients with Chronic Heart Failure: Results of the Bio-SHiFT Study. Journal of the American Society of Echocardiography, 2019, 32, 1000-1009.	2.8	7
203	Improved detection of viable myocardium with fluorodeoxyglucose-labeled single-photon emission computed tomography in a patient with hibernating myocardium: Comparison with rest-redistribution thallium 201-labeled single-photon emission computed tomography. Journal of Nuclear Cardiology, 1997, 4, 178-179.	2.1	6
204	Effect of coronary artery bypass surgery on myocardial perfusion and ejection fraction response to inotropic stimulation in patients without improvement in resting ejection fraction. American Journal of Cardiology, 2000, 86, 490-494.	1.6	6
205	Trends in incidence of infective endocarditis at the Medical Center of Alkmaar. Netherlands Heart Journal, 2015, 23, 548-554.	0.8	6
206	In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment. Netherlands Heart Journal, 2017, 25, 634-642.	0.8	6
207	Echocardiographic Studies of Dobutamine-Induced ST-Segment Elevation Before and After Coronary Artery Bypass Grafting in Patients with Old Q-Wave Myocardial Infarction. Journal of the American Society of Echocardiography, 1999, 12, 48-54.	2.8	5
208	Reply to Huang. American Heart Journal, 2011, 161, e3.	2.7	5
209	Diagnostic and Therapeutic Usefulness of Coronary Computed Tomography Angiography in Out-Clinic Patients Referred for Chest Pain. American Journal of Cardiology, 2015, 116, 30-36.	1.6	5
210	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis, 2020, 293, 35-41.	0.8	5
211	The challenge of choosing in cardiovascular risk management. Netherlands Heart Journal, 2022, 30, 47-57.	0.8	5
212	Time Course of Functional Recovery of Stunned and Hibernating Segments After Surgical Revascularization. Circulation, 2001, 104, .	1.6	5
213	Clinical experience with Albunex: a standard echocontrast agent for intravenous and intracoronary use. American Journal of Cardiac Imaging, 1991, 5, 217-23.	0.2	5
214	Myocardial contrast echocardiography can depict thebesian vein outflow in humans. American Heart Journal, 1992, 123, 1373-1374.	2.7	4
215	Dobutamine stress thallium-201 single-photon emission tomography versus echocardiography for evaluation of the extent and location of coronary artery disease late after myocardial infarction. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 467-473.	6.4	4
216	A man with diabetes and heart failure. Lancet, The, 2004, 364, 636.	13.7	4

#	ARTICLE	IF	CITATIONS
217	Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	4
218	Associations between β -blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2019, 218, 92-99.	2.7	4
219	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	2.7	4
220	Correlation between septal midwall late gadolinium enhancement on CMR and conduction delay on ECG in patients with nonischemic dilated cardiomyopathy. <i>IJC Heart and Vasculature</i> , 2020, 26, 100474.	1.1	4
221	Colchicine for secondary prevention in coronary disease. <i>European Heart Journal</i> , 2021, 42, 1060-1061.	2.2	4
222	Hemodynamic Changes, Plasma Catecholamine Responses, and Echocardiographically Detected Contractile Reserve During Two Different Dobutamine-Infusion Protocols. <i>Journal of Cardiovascular Pharmacology</i> , 1997, 29, 808-813.	1.9	4
223	Myocardial contrast echocardiography during hyperemia. <i>Coronary Artery Disease</i> , 1990, 1, 573-578.	0.7	3
224	Dobutamine stress-redistribution-reinjection versus rest-redistribution thallium-201 SPECT in the assessment of myocardial viability. <i>International Journal of Cardiovascular Imaging</i> , 1997, 13, 59-64.	0.6	3
225	Discriminative Power of the HEART Score for Obstructive Coronary Artery Disease in Acute Chest Pain Patients Referred for CCTA. <i>Critical Pathways in Cardiology</i> , 2016, 15, 6-10.	0.5	3
226	Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail. <i>Netherlands Heart Journal</i> , 2022, 30, 25-37.	0.8	3
227	Comparison of thallium-201 rest-redistribution SPECT and FDG SPECT in predicting functional recovery after revascularization. <i>Journal of the American College of Cardiology</i> , 1996, 27, 300-301.	2.8	2
228	Prediction of reversibility of wall motion abnormalities after revascularization using F18-fluorodeoxyglucose single photon emission computed tomography. <i>European Heart Journal</i> , 1996, 17, 480-481.	2.2	2
229	Coronary-Artery Bypass Surgery with Internal-Thoracic-Artery Grafts. <i>New England Journal of Medicine</i> , 1996, 334, 1609-1610.	27.0	2
230	One-year mortality after a first visit to a cardiology outpatient clinic: a useful performance indicator?. <i>Netherlands Heart Journal</i> , 2009, 17, 52-55.	0.8	2
231	Long-term Clinical Outcome and MIBI SPECT Parameters in Percutaneous Coronary Interventions. <i>Netherlands Heart Journal</i> , 2011, 19, 68-72.	0.8	2
232	Coronary Artery Pseudoaneurysm: Closure With Pericardium-Covered Stents, Guided by Cardiac Computed Tomography Angiography. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1014.e11-1014.e12.	1.7	2
233	Long-Term Follow-Up of the Randomized (BIOMArCS-2) Glucose Trial. <i>Circulation</i> , 2016, 134, 984-986.	1.6	2
234	Exercise Electrocardiogram Neither Predicts Nor Excludes Coronary Artery Disease in Women with Low to Intermediate Risk. <i>Journal of Women's Health</i> , 2018, 27, 476-484.	3.3	2

#	ARTICLE	IF	CITATIONS
235	Identification of Patients With Improvement of LVEF and Heart Failure Symptoms by Combined Low-High Dose Dobutamine Echocardiography. Journal of the American College of Cardiology, 1998, 31, 82A.	2.8	2
236	Prediction of Improvement of Left Ventricular Function and Heart Failure Symptoms by FDG SPECT. Journal of the American College of Cardiology, 1998, 31, 300A.	2.8	2
237	Detection of myocardial viability with F-18-fluorodeoxyglucose and single photon emission computed tomography. Giornale Italiano Di Cardiologia, 1997, 27, 1181-6.	0.2	2
238	The value of haemostatic markers in the triage of patients with chest pain presenting with a normal or non-diagnostic ECG. Heart, 2005, 91, 1215-1216.	2.9	1
239	Infarct size in primary angioplasty without on-site cardiac surgical backup versus transferal to a tertiary center: a single photon emission computed tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 237-243.	6.4	1
240	ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY. Journal of the American College of Cardiology, 2019, 73, 138.	2.8	1
241	Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e71-e71.	3.0	1
242	Synthetic Peer Benchmarking for Diversified Private Equity Programs. Journal of Alternative Investments, 0, , .	0.5	1
243	IGF-1 is not related to long-term outcome in hyperglycemic acute coronary syndrome patients. Diabetes and Vascular Disease Research, 2021, 18, 147916412110474.	2.0	1
244	937-4 Combined Use of Dobutamine Stress Echocardiography and Myocardial Contrast Echocardiography. Journal of the American College of Cardiology, 1995, 25, 159A-160A.	2.8	0
245	Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic. International Journal of Cardiovascular Interventions, 1999, 2, 223-230.	0.5	0
246	Dobutamine stress echocardiography is a valuable diagnostic test for predischage risk assessment in low-risk chest pain patients. Evidence-based Cardiovascular Medicine, 2003, 7, 203-205.	0.0	0
247	Dutch Randomized Trial on Off-Site Primary PCI. American Journal of Cardiology, 2008, 102, 1115.	1.6	0
248	TCT-176: Access and non-Access Site Bleeding in Acute Coronary Syndrome Patients Treated with a Novel Actively Reversible Factor IXa Inhibitor. Results from the RADAR Trial. Journal of the American College of Cardiology, 2011, 58, B47.	2.8	0
249	Intensive glucose regulation does not reduce enzymatic infarct size in hyperglycemic acute coronary syndromes: results of the randomized BIOMARCS-2 glucose trial. European Heart Journal, 2013, 34, P467-P467.	2.2	0
250	Dehiscence of mitral valve annuloplasty: a three-dimensional diagnosis. European Journal of Cardio-thoracic Surgery, 2014, 45, 393-393.	1.4	0
251	P4687Midwall late gadolinium enhancement in both nonischemic cardiomyopathy and ischemic heart disease. European Heart Journal, 2018, 39, .	2.2	0
252	Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies Attenuate Arterial Wall Inflammation In Statin Intolerant Patients In Absence Of Crp Change. Atherosclerosis, 2019, 287, e12.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries. European Heart Journal, 2021, 42, .	2.2	0
254	P2315 The added value of pre-discharge dobutamine stress echocardiography in the long-term risk stratification of chest pain patients. European Heart Journal, 2003, 24, 447.	2.2	0
255	P400 Myocardial beta-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo using (S)-611C9CGP 12388 and positron emission tomography. European Heart Journal, 2003, 24, 51.	2.2	0
256	Diagnostiek bij hartfalen. , 2007, , 71-93.		0
257	Preliminary clinical experience with intracoronary AlbunexR: a standardized echocontrast agent. Developments in Cardiovascular Medicine, 1993, , 109-120.	0.1	0
258	Assessment of Myocardial Viability by Pharmacological Stress Echocardiography. Developments in Cardiovascular Medicine, 1995, , 103-115.	0.1	0
259	Prediction of Improvement in Global and Regional Ventricular Function after Revascularization with FDG SPECT. , 1997, , 173-178.		0
260	FDG SPECT to Assess Myocardial Viability. Developments in Cardiovascular Medicine, 1998, , 249-260.	0.1	0
261	Assessment of myocardial viability by FDG imaging with SPECT. Developments in Cardiovascular Medicine, 1998, , 299-309.	0.1	0
262	Relation between Viability, Improvement of Lvef and Heart Failure Symptoms after Revascularization. , 1999, , 223-227.		0
263	P595 Characteristics of the right ventricle in patients with nonischemic dilated cardiomyopathy. European Heart Journal, 2019, 40, .	2.2	0
264	Relation between pharmacological stress ECG, 13NH3-PET/CT outcome and the occurrence of cardiac events during follow-up in women with chest pain. Nuclear Medicine Communications, 2020, 41, 783-789.	1.1	0
265	Emphasis on prevention: how to approach residual cardiovascular risk. Netherlands Heart Journal, 2022, 30, 1-2.	0.8	0
266	Heart failure: chapter 4. Evaluation of patients with suspected heart failure. Netherlands Heart Journal, 2004, 12, 412-416.	0.8	0
267	Coronary-artery bypass surgery with internal-thoracic-artery grafts. New England Journal of Medicine, 1996, 334, 1609-10.	27.0	0